Mark E Schurdak from Warrendale, PA, age 64

Method Of Killing Cancer Cells
view source
US Patent:

20040180844, Sep 16, 2004
Filed:

Mar 10, 2003
Appl. No.:

10/385163
Inventors:

Stephen Fesik - Gurnee IL, US
Donald Halbert - Libertyville IL, US
Randy Metzger - Gurnee IL, US
Jeffrey McDowell - Grayslake IL, US
Mark Schurdak - Antioch IL, US
Aparna Sarthy - Waukegan IL, US
International Classification:

A61K048/00
US Classification:

514/044000
Abstract:

A method of killing cancer cells comprising inhibiting the function of a gene selected from the group consisting of CDK8, STK33, PRKCM, PRKACA, ACVR1B, CDK5R1, CDC42BPB, MPP6, and CDC42BPA; pharmaceutical compositions comprising an inhibitor of the same, and a method of detecting cellular hyperplasia.

Method Of Killing Cancer Cells
view source
US Patent:

20040180848, Sep 16, 2004
Filed:

Mar 9, 2004
Appl. No.:

10/796177
Inventors:

Stephen Fesik - Gurnee IL, US
Donald Halbert - Libertyville IL, US
Randy Metzger - Gurnee IL, US
Jeffrey McDowell - Grayslake IL, US
Mark Schurdak - Antioch IL, US
Aparna Sarthy - Waukegan IL, US
International Classification:

A61K048/00
US Classification:

514/044000
Abstract:

A method of killing cancer cells comprising inhibiting the function of a gene selected from the group consisting of CDK8, STK33, PRKCM, PRKACA, ACVR1B, CDK5R1, CDC42BPB, MPP6, and CDC42BPA; pharmaceutical compositions comprising an inhibitor of the same, and a method of detecting cellular hyperplasia.

Continuous Format High Throughput Screening
view source
US Patent:

59768134, Nov 2, 1999
Filed:

Dec 12, 1997
Appl. No.:

8/990168
Inventors:

Bruce A. Beutel - Libertyville IL
Mark E. Schurdak - Antioch IL
Martin J. Voorbach - Vernon Hills IL
David J. Burns - Round Lake Park IL
Mary K. Joseph - Libertyville IL
Assignee:

Abbott Laboratories - Abbott Park IL
International Classification:

G01N 3353
US Classification:

435 71
Abstract:

Continuous format high throughput screening (CF-HTS) using at least one porous matrix allows the pharmaceutical industry to simultaneously screen large numbers of chemical entities for a wide range of biological or biochemical activity. In addition, CF-HTS is useful to perform multi-step assays.

6-Aryl-7-Substituted-3-(1H-Pyrazol-5-Yl)-7H-[1,2,4]Triazolo[3,4-B][1,3,4]Thiadiazines As Inhibitors Of The Stat3 Pathway With Anti-Proliferative Activity
view source
US Patent:

20200339602, Oct 29, 2020
Filed:

Apr 10, 2020
Appl. No.:

16/846089
Inventors:

- Pittsburgh PA, US
Peter Wipf - Pittsburgh PA, US
Jennifer Rubin Grandis - Pittsburgh PA, US
Matthew G. LaPorte - Pittsburgh PA, US
Paul A. Johnston - Sewickley PA, US
Mark E. Schurdak - Pittsburgh PA, US
Raffaele Colombo - Pittsburgh PA, US
Assignee:

University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:

C07D 513/04
A61P 35/00
Abstract:

Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.

6-Aryl-7-Substituted-3-(1H-Pyrazol-5-Yl)-7H-[1,2,4]Triazolo[3,4-B][1,3,4]Thiadiazines As Inhibitors Of The Stat3 Pathway With Anti-Proliferative Activity
view source
US Patent:

20190100535, Apr 4, 2019
Filed:

Jan 15, 2016
Appl. No.:

15/543573
Inventors:

- Pittsburgh PA, US
Peter Wipf - Pittsburgh PA, US
Jennifer Rubin Grandis - Pittsburgh PA, US
Matthew G. LaPorte - Pittsburgh PA, US
Paul A. Johnston - Sewickley PA, US
Mark E. Schurdak - Pittsburgh PA, US
Raffaele Colombo - Pittsburgh PA, US
Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCTION - Pittsburgh PA
International Classification:

C07D 513/04
A61P 35/00
Abstract:

Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.

view source

Mark E Schurdak